(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Oldest evidence of human fire-making discovered at site in England - 22 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- 3Joshua Made Last-Second Seat Change That Saved His Life
- 4See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- 5The Most Vital Crossroads in Olympic History
- January’s full wolf supermoon and the Quadrantid meteor shower will start off the new year
- 4 African Vacationer Locations
- Share your pick for the miniature headphones that you generally suggest!
- German finance minister sees advantages of smartphones in schools
- Philippines evacuates 3,000 villagers after volcano activity raises alert level
- NASA Perseverance rover sees megaripples on Mars | Space photo of the day for Jan. 7, 2026.
- From White Elephant to Favorite Things parties, here are all the rules you need to know every kind of gift exchange
- Lily Allen 2026 'West End Girl' Tour: How to get tickets, prices, presale info and more
- The 15 Most Compelling Books in History
